Sulfobutylether-β-cyclodextrin

This review presents the early history, the motivation, the research and some of the backstories behind the discovery and development of sulfobutylether-β-cyclodextrin as a novel parenterally safe solubilizer and stabilizer. A specific sulfobutylether-β-cyclodextrin with an average degree of 6.5 sul...

Descripción completa

Detalles Bibliográficos
Autores principales: Stella, Valentino J., Rajewski, Roger A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196545/
https://www.ncbi.nlm.nih.gov/pubmed/32376442
http://dx.doi.org/10.1016/j.ijpharm.2020.119396
_version_ 1783528740798595072
author Stella, Valentino J.
Rajewski, Roger A.
author_facet Stella, Valentino J.
Rajewski, Roger A.
author_sort Stella, Valentino J.
collection PubMed
description This review presents the early history, the motivation, the research and some of the backstories behind the discovery and development of sulfobutylether-β-cyclodextrin as a novel parenterally safe solubilizer and stabilizer. A specific sulfobutylether-β-cyclodextrin with an average degree of 6.5 sulfobutyl-groups variably substituted on the 2-, 3- and 6-hydroxyls of the seven glucopyranose (dextrose) units of β-cyclodextrin, is known by its commercial name, Captisol®. Today it is in 13 FDA approved injectables and numerous clinical candidates. It is also an example of a novel product discovered and initially preclinically developed at an academic institution.
format Online
Article
Text
id pubmed-7196545
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71965452020-05-04 Sulfobutylether-β-cyclodextrin Stella, Valentino J. Rajewski, Roger A. Int J Pharm Article This review presents the early history, the motivation, the research and some of the backstories behind the discovery and development of sulfobutylether-β-cyclodextrin as a novel parenterally safe solubilizer and stabilizer. A specific sulfobutylether-β-cyclodextrin with an average degree of 6.5 sulfobutyl-groups variably substituted on the 2-, 3- and 6-hydroxyls of the seven glucopyranose (dextrose) units of β-cyclodextrin, is known by its commercial name, Captisol®. Today it is in 13 FDA approved injectables and numerous clinical candidates. It is also an example of a novel product discovered and initially preclinically developed at an academic institution. Elsevier B.V. 2020-06-15 2020-05-04 /pmc/articles/PMC7196545/ /pubmed/32376442 http://dx.doi.org/10.1016/j.ijpharm.2020.119396 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Stella, Valentino J.
Rajewski, Roger A.
Sulfobutylether-β-cyclodextrin
title Sulfobutylether-β-cyclodextrin
title_full Sulfobutylether-β-cyclodextrin
title_fullStr Sulfobutylether-β-cyclodextrin
title_full_unstemmed Sulfobutylether-β-cyclodextrin
title_short Sulfobutylether-β-cyclodextrin
title_sort sulfobutylether-β-cyclodextrin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196545/
https://www.ncbi.nlm.nih.gov/pubmed/32376442
http://dx.doi.org/10.1016/j.ijpharm.2020.119396
work_keys_str_mv AT stellavalentinoj sulfobutyletherbcyclodextrin
AT rajewskirogera sulfobutyletherbcyclodextrin

Ejemplares similares